<DOC>
	<DOCNO>NCT00363181</DOCNO>
	<brief_summary>Medications like olanzapine associate development weight gain diabetes patient . It know increase risk develop diabetes direct effect insulin simply related weight gain . We hope learn study whether olanzapine directly slow insulin secretion pancreas , thereby increase risk develop diabetes .</brief_summary>
	<brief_title>Side Effects Antipsychotic Medications</brief_title>
	<detailed_description>Objectives : The use atypical antipsychotic associate increase weight gain , development type-2 diabetes , , rare case , diabetic ketoacidosis . It clear change direct function antipsychotic either insulin action insulin secretion , simply related ability induce weight gain population increase risk develop hyperglycemia . The objective investigation determine treatment atypical antipsychotic olanzapine impairs ability pancreatic beta cell increase insulin secretory response grade increase plasma glucose concentration non-diabetic , insulin resistant individual . In addition , compare range insulin-mediated glucose uptake ( IMGU ) olanzapine-treated versus non-antipsychotic treated patient . Research Plan Methods : 120 subject psychiatric disorder enrol ; 60 patient olanzapine 60 patient similar psychiatric diagnosis different antipsychotic medication ( ziprasidone , risperidone aripiprazole ) . All subject fast plasma glucose concentration &lt; 126 mg/dL , medication direct effect IMGU . Subjects admit General Clinical Research Center ( GCRC ) Stanford Medical Center evaluate insulin suppression test ( IST ) determine IMGU . Subjects steady state plasma glucose ( SSPG ) concentration IST &gt; 180 mg/dL define insulin resistant . From population subject , 15 patient olanzapine 15 patient antipsychotic , return GCRC determine glucose-stimulated insulin secretory dose-response curve ( GS-ISR ) . The GS-ISR glucose concentration compare subject olanzapine ( n=15 ) antipsychotic ( n=15 ) analysis variance . Analyses 120 subject screen insulin resistance compare 1 ) mean distribution SSPG concentration olanzapine non-olanzapine treated patient psychiatric diagnosis ; 2 ) mean two experimental group psychiatric diagnosis Dr. Reaven ’ data base volunteer without psychiatric disorder .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Schizophrenia Spectrum Other Psychotic Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Participants 3066 year age Body mass index ( BMI ) &gt; 25 &lt; 35 kg/m2 . Fasting plasma glucose concentration &lt; 126 mg/dL Stable one follow psychiatric medication : Olanzapine ( Zyprexa® ) , Ziprasidone ( Geodon® ) , Aripiprazole ( Abilify® ) , Risperidone ( Risperdal® ) Stable psychiatric medication least 3 month Medications directly affect insulinmediated glucose disposal Intense suicidal impulses/intent Alcohol substance abuse 3 month . Major medical problem , i.e. , clinically unstable medical disorder condition ; cardiovascular , hepatic , renal , gastrointestinal , pulmonary , endocrine systemic disease would , investigator 's clinical judgment interfere endocrine measure obtain study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Insulin resistance</keyword>
	<keyword>Metabolic problem</keyword>
	<keyword>Weight gain</keyword>
	<keyword>Mental health problem</keyword>
	<keyword>Mental disorder</keyword>
	<keyword>Antipsychotic medication</keyword>
	<keyword>Olanzapine</keyword>
</DOC>